Navigation Links
Kensey Nash Announces Appointment of Chief Financial Officer
Date:3/5/2009

EXTON, Pa., March 5 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY), a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, is pleased to announce today the appointment of Michael Celano, C.P.A. as Chief Financial Officer effective March 10, 2009.

"We are looking forward to Mike joining our management team where his extensive and broad experience as a partner with KPMG and Arthur Andersen in the life sciences practice along with his success as a CFO in the private sector will be a valuable resource," stated Joe Kaufmann, President and CEO. "On behalf of the Board, I would like to welcome Mike to the Kensey Nash management team."

Mr. Celano has extensive experience in life sciences where he spent 24 years in public accounting as a partner with KPMG and Arthur Andersen holding life science leadership positions in both firms. He served more than forty life sciences clients and was the lead audit partner for sixteen different public life sciences companies. In addition, he was the lead partner on twenty-two initial public offerings, and he has worked on over 100 public offerings and over sixty corporate partner and merger/acquisition transactions. After his public accounting experience, Mr. Celano became the Chief Financial Officer for BioRexis Pharmaceutical Corporation, a privately held venture-funded company that was acquired by Pfizer in February 2007. Most recently, Mr. Celano was the Managing Director, National Life Sciences Practice, for Aon Corporation of Philadelphia, PA. While at Aon, Mr. Celano led business development activities in key U.S. markets focused on product/clinical trial and D&O enterprise risk. Mr. Celano is also on the board of a publicly held medical diagnostics company.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
2. Kensey Nash Announces Director Resignation
3. Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference
4. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
5. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference
6. Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance
7. Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
8. Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference
9. Corrected Press Release: Kensey Nash to Present at the Bank of America 2008 Health Care Conference
10. Kensey Nash to Present at the Bank of America 2008 Health Care Conference
11. Kensey Nash Reports Third Quarter Record Revenue and Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... To ... infrastructure. Most providers, however, are unsure how to move forward, given the need ... define a path forward tailored to an organization’s specific needs. , PYA Principal ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... SpiritQuest Sedona ... heart of West Sedona, surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and ... partner properties – the Lodge at Sedona as well as the Sedona Rouge, both ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... An ... may expose a possible link between head and neck cancer in individuals with unhealthy ... the study were evaluated based on whether they had gum disease, brushed their teeth ...
(Date:6/23/2016)... ... 23, 2016 , ... SyncDog, Inc. , the leading ... is featured in the current issue of Silicon Review magazine. Silicon ... technology solutions and features them in their magazine. The magazine allows top-level executives ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
(Date:6/23/2016)... , June 23, 2016 Leading ... that address medical conditions resulting from a breakdown ... has appointed Greg Doyle as chief ... Leading BioSciences, executive management team and board of ... chief financial officer. He will provide continued leadership ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Alkermes PLC ... AMAG ), IDEXX Laboratories Inc. (NASDAQ: IDXX ... Learn more about these stocks by accessing their free trade ...
Breaking Medicine Technology: